Autoimmune Diseases  >>  Smyraf (peficitinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Smyraf (peficitinib) / Astellas, Maruho
NCT01711814 / 2011-006021-23: A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Completed
2
611
US, Europe, RoW
peficitinib, ASP015K
Astellas Pharma Global Development, Inc., Janssen Biotech, Inc.
Arthritis, Rheumatoid
03/16
03/16

Download Options